N/A N=28 Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics
Breast Cancer
Primary: Expression of Estrogen Receptor (ER-beta) — 67.1; 63.3; 45.0; 62.0 percentage of cells
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=500 Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women
Respiratory Syncytial Virus Infections
Primary: Number of Subjects With Solicited Local Symptoms — 62; 68; 104; 104 Participants
Phase 2 N=44 GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: 6 Months Progression-free Survival (PFS) — 0; 5 percentage of patients
N/A N=980 A Randomized Trial Comparing Metered Dose Inhalers and Breath Actuated Nebulizers
Asthma
Primary: Number of Participant's Admitted to the Hospital for Further Treatment — 53; 57 Participants admitted to the Hospital
Phase 3 N=588 A Study in Participants With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) — 61.9; 76.7; 78.1 Percent of participants
N/A N=190 Comparison of Interventions to Promote Health in Workers
Health Behavior
Primary: Quality of Life — 71.5; 68.5; 72; 72 units on a scale
Phase 3 N=802 Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
Bladder Cancer
Primary: Recurrence Rate at 2 Years — 112; 121; 183; 150 Participants — p=0.1068
N/A N=7 Early Detection and Prevention of Mood Disorders in Children of Parents With Bipolar Disorder
Bipolar Disorder · Depression
Primary: K SADS-Present Version (KSADS-P) — 0; 2; 1; 0 participants
Phase 2 N=22 Oxytocin Treatment of Alcohol Dependence
Alcohol Dependence
Primary: Proportion of Heavy Drinking Days — 0.3072; 0.5914 proportion of days per week
Phase 2 N=35 Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma
Uterine Cervical Cancer
Primary: Toxicity (Number of Participants With Serious Adverse Events) — 10 Participants
Phase 2 N=24 Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
Breast Cancer
Primary: Estimate Efficacy of Capecitabine 7/7 in Combination With Lapatinib in Patients With HER2 Overexpressed/Amplified, Trastuzumab-refractory, Metastatic Breast Cancer as…
Phase 3 N=1,307 A Study in Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) — 40.2; 69.6; 61.2 percentage of participants — p=0.001
Phase 4 N=92 Acute Psychotherapy for Bipolar II Depression
Bipolar Disorder · Depression
Primary: Remission — 16; 13 Participants — p=<0.0001
Phase 2 N=60 Study of LY3016859 in Participants With Diabetic Nephropathy
Diabetic Nephropathy
Primary: Part B:Change From Baseline in Proteinuria — 1.5; -0.4; 0.1; 0.7 grams per 12 hour (g/12 hour) — p=0.0449
Phase 2 N=55 A Study of Advanced or Metastatic Non-small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Overall Tumor Response - Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] — 9.1 percentage of…